

# John Paul Seenan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3125107/publications.pdf>

Version: 2024-02-01

13  
papers

91  
citations

1684188

5  
h-index

2053705

5  
g-index

13  
all docs

13  
docs citations

13  
times ranked

140  
citing authors

#	ARTICLE	IF	CITATIONS
1	Disease monitoring of biologic treatment in IBD: early impact and future implications of COVID-19 pandemic. <i>Frontline Gastroenterology</i> , 2021, 12, 345-347.	1.8	8
2	P153...Low rates of subtherapeutic drug levels are observed with proactive therapeutic drug monitoring of infliximab. , 2021, , .		0
3	P154...Vedolizumab drug levels are not associated with outcomes or disease activity in inflammatory bowel disease. , 2021, , .		0
4	P150...Adalimumab therapeutic drug monitoring “ does time of testing matter?. , 2021, , .		0
5	Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2067-2075.	2.8	17
6	Pathogenesis of Musculoskeletal Deficits in Children and Adults with Inflammatory Bowel Disease. <i>Nutrients</i> , 2021, 13, 2899.	4.1	11
7	P152...Low rates of subtherapeutic drug levels are observed with proactive therapeutic drug monitoring of adalimumab. , 2021, , .		0
8	P275...Analysis of exclusive enteral nutrition formulas in Crohn’s disease “ new insights into dietary triggers. , 2021, , .		0
9	PMO-21...Impact of COVID-19 on infliximab prescribing practices in inflammatory bowel disease. , 2021, , .		0
10	Acute interstitial nephritis secondary to vedolizumab. <i>BMJ Case Reports</i> , 2021, 14, e243568.	0.5	5
11	Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn’s disease “ new insights into dietary disease triggers. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 935-947.	3.7	49
12	PTH-132...High rates of clinical response are maintained after switching from originator to biosimilar infliximab. , 2019, , .		0
13	PTH-133...herapeutic drug monitoring supports clinical decision making when employed before and after biosimilar infliximab switching. , 2019, , .		1